FDA and NIH studying why omicron variant may affect rapid tests
The U.S. Food and Drug Administration (FDA) says "studies are underway" examining why the omicron variant may make rapid COVID tests less effective.
Stephanie Caccomo, a spokeswoman for the FDA, told ABC News the agency will collaborate with the National Health Institute's (NIH) Rapid Acceleration of Diagnostics (RADx) program and select a variety of rapid tests to study.
However, Dr. Bruce Tromberg of the NIH -- who is leading these studies -- said Americans shouldn't be discouraged from using rapid tests.
Tromberg told ABC's Dr. Mark Abdelmalek that rapid tests are "extremely powerful and effective" at identifying people who are infected, with COVID which prevents them from spreading the virus.
"I have confidence that the tests that we have on our shelves can pick up omicron," Tromberg added.
Testing companies also stressed that their tests still work to detect omicron, with Abbott saying Tuesday that the company has tested the popular BinaxNOW rapid test and found "equivalent sensitivity" compared to prior variants.
-ABC News' Sony Salzman